The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the tumour burden in B-CLL, a new niche may be found -as a potentially curative agent in which its tumour purging ability in vivo combines with its role as a conditioning agent in nonmyeloablative transplantation. Review of the literature shows that alemtuzumab has unique advantages as a method of depleting malignant lymphocytes, including those in patients resistant to conventional chemotherapy. Alemtuzumab can also be used in BMT for depletion of normal T and B lymphocytes of both the recipient and donor for prevention of graft rejection and GVHD. It allows good stem cell recovery with resultant rapid engraftment, has a low risk of EBVtriggered secondary malignancy and does not interfere with blood stem cell mobilisation. As a method of eliminating the malignant clone in B-CLL, alemtuzumab has shown remarkable efficacy in heavily pre-treated patients, a number of whom have progressed to autologous or allogeneic transplantation. Efficacy data are shown within the context of other transplantation data for B-CLL. These results indicate that the combination of tumour-depleting and immunosuppressive properties of alemtuzumab should be explored, with the hope of providing improved treatment options for elderly patients with advanced B-CLL or indolent lymphoma whose prognosis is too poor currently to allow treatment with traditional regimens of high-dose myeloablative chemotherapy.
Transplantation of allogeneic bone marrow or peripheral blood stem cells (PBSC) for leukaemia and lymphoma has the potential to eradicate the malignant clone by permitting supralethal chemotherapy, and/or facilitating graft-versustumour effects.
1,2 Transplantation aims to promote rapid engraftment of normal stem cells capable of reconstituting normal haematopoiesis, while avoiding clinically significant graft-versus-host disease (GVHD) or graft rejection. GVHD, which can be lethal in either its acute or chronic form, can be minimised by depleting immunocompetent donor T cells. 3, 4 Graft rejection can be prevented if host T cells are extensively removed prior to transplantation as demonstrated in mice 5 and in humans. 6 Traditionally, this has been achieved by high-dose 'myeloablative' chemoradiotherapy which eliminates both the host immune system and host stem cells. However, this causes a period of considerable risk from procedure-related toxicity and mortality as well as viral, bacterial, fungal infections and various parasites. Building on early work using animal models of BMT, 7, 8 nonmyeloablative conditioning aims to minimise procedure-related toxicity, to narrow the period of high risk, and to facilitate the induction of bilateral transplantation tolerance of host-versus-graft and graft-versushost. By retaining host stem cells, but depleting both host and graft of mature T cells, neither graft rejection nor GVHD should occur, and normal haematopoiesis will be more rapidly resumed. The purine analogue fludarabine is one of the key constituents of nonmyeloablative conditioning, 9, 10 to which alemtuzumab may now be added. The Campath-1 series of Mabs is directed against human CD52, an antigen expressed on T, B and NK cells, 11 but not on haematopoietic stem cells. 12 The original rat IgM antibody, Campath-1M, was used with human complement for T cell depletion in vitro. Campath-1G (rat IgG2b) was developed for in vivo depletion of host T cells to prevent rejection. It was subsequently humanised by genetic engineering to create Campath-1H (alemtuzumab). 13 In B-CLL, alemtuzumab can be used to purge malignant cells from the host. It is particularly effective in eliminating such cells from blood and marrow, thus allowing harvesting to be carried out for the purposes of autologous transplantation. The future may also see it used more extensively, in the host and/or in the graft, prior to allogeneic transplantation for B-CLL.
Alemtuzumab as treatment for lymphoid malignancies
Alemtuzumab is currently approved only for the treatment of chronic lymphocytic leukaemia (CLL) resistant to alkylating agents and fludarabine. In a pivotal study conducted in 93 patients with advanced disease who had failed these other therapies, alemtuzumab (30 mg) was administered three times per week for up to 12 weeks and gave an overall response rate of 33%.
14 Other studies have shown even better results in the treatment of T cell prolymphocytic leukaemia (T-PLL), 15 first-line treatment of CLL 16 and in combination with fludarabine 17 or rituximab. 18 Studies in non-Hodgkin's lymphoma were less successful because alemtuzumab did not have a significant impact on bulky lymph nodes at the doses used, though it still cleared tumour cells from blood and bone marrow. 
Alemtuzumab as an agent to avoid GVHD in allogeneic transplantation
T cell depletion using Campath-1 antibodies can simply and effectively reduce GVHD. Depletion can be carried out in vitro or in vivo, without the use of any devices or complex manipulations, and allowing high recovery of stem cells. Alternative depletion methods may result in stem cell loss, risk of infection or technical problems due to in vitro manipulation, thus increasing the risk of graft failure. They include positive selection of CD34 + stem cells, purging of T cells or combinations of both. Direct methods for purging of T cells are very varied. [20] [21] [22] [23] Some, such as elutriation, may remove too few T cells to effectively control GVHD, [24] [25] [26] and may also considerably reduce CD34 + cell counts, 27, 28 which may affect the rate and speed of engraftment. Even commercially available CD34 + selection devices can give low yields of important cells. For example, Clarke et al 29 compared in vitro T depletion by Campath-1M plus complement with CD34 + selection. They found similar depletion of T cells and recovery of CD34 + cells, but a significantly better recovery of colony-forming cells following the Campath-1M treatment (Table 1) . A major advantage of using alemtuzumab is that CD34 negative progenitor cells should not be lost. It appears that there are such cells which possess full reconstitutive capacity and it is suggested that they are not so easily exhausted as CD34 + cells in a pre-immune foetal transplantation model. [30] [31] [32] Human CD34 negative cells might provide a reservoir with longer or more durable reconstitution capabilities. Until the nature and potential benefit of these cells has been established, it may be prudent to use selection methods that deplete mature lymphocytes rather than ones which select for CD34 alone. Campath-1G can be used to condition the recipient using an intravenous infusion around the transplantation period, or simply mixed with the stem cells. 6, [33] [34] [35] Under such circumstances, it depletes both host and donor lymphocytes. In recent years, the rat antibody Campath-1G has been replaced by alemtuzumab which has a significantly longer half-life 36 and effectively prevents GVHD even when administered up to a week before the transplant.
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Immune reconstitution and infectious complications
In addition to the risk of GVHD, transplantation carries the risk of delayed immune reconstitution with increased susceptibility to infections, particularly viral and fungal infections. The most serious viral complications include cytomegalovirus (CMV) disease and Epstein-Barr virustriggered (EBV) lymphoproliferative disease, which is frequently fatal. However, this latter complication is rare following autologous transplantation presumably because there is no need to use post-transplant immunosuppression for prevention or treatment of GVHD. In allogeneic transplantation, EBV may also be introduced with the donor B lymphocytes. Extensive surveys reviewing nearly 20 000 transplants have shown that an increased risk of this secondary malignancy is strongly associated with T cell depletion compared with the infusion of unmanipulated marrow. 38 Dissecting out the risks associated with different methods of T cell depletion shows that the risk is highest with protocols which retain B cell populations, eg Erosetting or antibodies specific to T cells, and lowest when methods are used which also eliminate donor B cells, such as the Campath-1 series of antibodies, elutriation, or direct selection of stem cells. In a comparison of E-rosetting vs Campath-1, the risk was as high as 29% in the E-rosette group and only 1.3% in the Campath-1 group, which is little different from the rate in patients transplanted with unmodified marrow. 39 The additional depletion of B cells appears to be beneficial, possibly because it reduces virus load, or because it reduces virus target until the time when T cells begin to regenerate, at which time the immunosurveillance is resumed.
In contrast to the low incidence of lymphoproliferative disease, reactivation of CMV is common and rapid in CMV seropositive patients after Campath-containing conditioning. 40, 41 Recent studies using alemtuzumab with reduced dose conditioning indicate that reactivation is often associated with symptoms such as pyrexia and cough, but not with CMV disease so long as pre-emptive therapy with ganciclovir is initiated promptly. [41] [42] [43] The risks of other infections, especially from respiratory viruses such as parainfluenza (PIV) and respiratory syncytial virus (RSV) may also be increased in patients who receive conditioning with alemtuzumab. 44 This is no doubt related to the impact of T cell depletion on immune regeneration. For example, a study of immune reconstitution after T cell-depleted PBSC transplantation showed that, while total T cell counts reached the normal range within the first few months post transplantation, CD4 counts and some T cell functions remained sub-normal for at least 1 year post transplant. 45 Delayed lymphocyte recovery may be further exacerbated by the switch from rat to humanised antibody, which may persist in the patient for several months post transplant. 36 Immune recovery is an area which requires further detailed studies in larger patient populations over longer periods of time. One promising approach, which may facilitate immunological reconstitution following transplantation, involves the use of IL-7, as has been shown using preclinical animal models. 46, 47 
Stem cell transplantation in B-CLL
CLL is a relatively benign B cell malignancy and most sufferers are elderly. The toxicity of myeloablative transplant conditioning regimens and the high risk of GVHD in this population have been considerable deterrents to the use of stem cell transplantation. However, high-dose regimens are now being replaced by well-tolerated procedures which are immunosuppressive rather than totally myeloablative, and are usually based on fludarabine, often in combination with cyclophosphamide, busulphan or other alkylating agents or low-dose radiation (nonmyeloablative stem cell transplants, NST). [48] [49] [50] [51] [52] [53] [54] [55] Conveniently, there is substantial overlap between these new preparative regimens and the drug schedules most effective in reducing tumour burden in B-CLL. Alemtuzumab is a prime example, because it is an effective antitumour agent for B cell malignancies and facilitates engraftment of allogeneic stem cells, particularly in the context of NST.
The introduction of a regimen using alemtuzumab to purge malignant cells in vivo also coincides with a number of other improvements in transplant procedures and in posttransplant supportive care, and the achievement of a deeper Table 2 Bone marrow transplants for non-Hodgkin's lymphoma or chronic lymphocytic leukaemia Bone Marrow Transplantation understanding of the nature of engraftment and the reconstitution of the immune system it entails. As shown in Table 2 , when CLL patients are offered BMT at a relatively young age, both autologous and allogeneic transplants can achieve success in promoting engraftment and remission. 56 
Autologous transplantation in B-CLL
Autologous transplantation studies in B-CLL, using standard high-dose preparative regimens in young patient cohorts (median 49 years, range 57 have confirmed the rapid engraftment possible with PBSC (13 patients) compared with bone marrow (three patients). Remission was confirmed at the molecular level using PCR to detect clone-specific IgG rearrangements. Successful autologous transplantation in B-CLL has also been carried out after high-dose chlorambucil in a 49-year-old patient with autoimmune complications. 58 Similarly, mobilised PBSC were observed to engraft 59 whether or not T cell depletion by CD34 + selection was carried out. One problem with autologous transplantation using PBSC in patients with advanced B-CLL is that, even with the increased numbers of stem cells available using cytokine mobilisation, it may not be possible to obtain sufficient cells for manipulation and rapid engraftment. In three of 17 patients studied by Scime et al, 60 the harvest was insufficient. The yield was greater in patients who had achieved a complete remission prior to transplant than in those in partial remission.
The use of purine analogues may compromise the yield of stem cells from some B-CLL patients, as demonstrated by Schey et al, 61 in a study in which 10 B-CLL patients were treated. Two of the 10 did not mobilise sufficient stem cells to allow selection to be carried out. Of the eight in whom selection of harvested cells was undertaken, only five had an adequate yield post selection to allow them to proceed to transplantation, and so underwent transplantation with a mix of selected and unselected 'back-up' cells.
In contrast, alemtuzumab did not interfere with PBSC mobilisation or harvesting in studies at the Royal Marsden NHS Trust. 62 All six patients gave good yields of PBSC and the purity of five was sufficient for subsequent autologous transplantation (Table 3 ). This group had been treated to maximum response with purine analogues (either fludarabine or pentostatin) but had retained persistent leukaemic infiltration of both blood and bone marrow. Alemtuzumab treatment allowed five patients to achieve complete haematological remission with no detectable CD5 + /CD19 + cells. Two patients with a previously rapid clinical course went immediately on to high-dose BEAM therapy (BCNU, etoposide, Ara-C and melphalan) followed by autologous transplantation with successful rapid engraftment. In three patients with no or minimal contamination with malignant cells, it was elected to observe subsequent progress before transplantation. The sixth patient who retained minimal residual disease went on to allogeneic transplantation from a matched, unrelated donor, after 5 months. The finding that alemtuzumab readily permits mobilisation for stem cell harvesting has been confirmed in another group of seven patients who proceeded to autologous PBSC transplantation after alemtuzumab therapy. 63 Two patients improved to have no detectable disease by sensitive 4-colour flow cytometry on repeated analysis (21, 23 and 34 months post alemtuzumab treatment).
Allogeneic transplantation in B-CLL
Allogeneic transplantation for B-CLL may have advantages for long-term disease-free survival due to potential eradi- cation of residual malignant cells by GVL effects. Harvesting of high numbers of donor stem cells is also possible. These advantages are offset by higher treatmentrelated risks using conventional myeloablative BMT, but the risks may be reduced by using NST. Further clinical experience is needed to assess the potential benefits of the NST regimen for improvement of disease-free survival.
In the first of the allograft studies shown in Table 2 , although remissions were achieved, the treatment-related mortality was considerable. Twelve patients died of early complications (GVHD, infection, haemorrhage, etc), while only three died of disease progression. The largest series of allografts of a cohort of 54 patients had 30 deaths, 25 of which were treatment-related and generally due to, or associated with, GVHD. 64 As shown, advances in engraftment have improved these results in later years, although, deaths from transplantrelated causes still outnumber those from progressive disease. 65, 66 With regard to survival, the follow-up is too short in most reported cases to say for certain whether the remissions are durable enough to constitute a cure. However, analysis of blood samples at the molecular level, which shows that the IgG rearrangement specific to the malignant clone is absent after transplant, is very encouraging. 67 Nonmyeloablative conditioning regimens in leukaemia/lymphoma are already showing some benefits. [49] [50] [51] [52] 54 Many of these improvements are due to decreased procedure-related toxicity in high-risk patients with heavily pre-treated advanced disease and in the elderly. However, GVHD remains a significant problem, with an incidence of grade 2-4 acute GVHD of 38%-60%, and is the primary cause of death. The addition of alemtuzumab to minimally immunosuppressive conditioning regimens may improve this aspect of transplant-related morbidity and mortality, as suggested in preliminary studies. In one, Campath-1G was added to the conditioning regimen, BEAM, 55 a protocol more commonly used to precede autologous transplantation. In these 12 patients, 10 with NHL and two with CLL, the combination of alemtuzumab and BEAM produced high remission rates (75%) and a notably low incidence of GVHD. Although follow-up is too short to draw conclusions about relapse rates, 75% survived and 67% remained event-free at a median of 1 year post-transplant. Extending this protocol into 30 lymphoma patients gave 67% overall survival and 48% event-free survival at 3 years with donor lymphocyte infusions (DLI) used to combat early relapse in nine cases. 68 These results compare well with the transplant-related mortality seen after autologous transplantation or conventional myeloablative allogeneic BMT. In an alternative regimen, alemtuzumab was added to nonmyeloablative conditioning using fludarabine and melphalan in 44 patients with high-risk leukaemia/lymphoma, 19 of whom had failed previous transplants. 37 Engraftment rates were high (95%) and GVHD was limited, with no cases of grade 3 or 4 disease, although one patient developed grade 4 GVHD after DLI used to treat relapse. Overall survival at 2 years was estimated to be 75%, with 11% non-relapse mortality. At a median follow-up of 9 months, 33 patients remained alive and in complete remission or with no evidence of progression. Response and freedom from relapse were greater in patients with lymphoma (HD, NHL or CLL) compared with those with myeloid leukaemias. Allogeneic BMT, especially NST in conjunction with alemtuzumab, may combine all benefits, thus possibly resulting in effective treatment of CLL and indolent lymphomas, based on the combined effects of alemtuzumab serving as antitumour as well as anti-rejection and anti-GVHD, all combined.
Alemtuzumab has been compared to anti-thymocyte globulin (ATG) as a means to reduce GVHD when used with fludarabine/TBI sub-myeloablative conditioning (TBI 450 cGy, on day Ϫ6 and fludarabine, 30 mg/m 2 /day on days Ϫ5 to Ϫ2). 69 Nine patients received ATG while 11 received alemtuzumab. Various haematological malignancies were treated, including six cases of NHL, one of CLL and two of HD. Acute GVHD was completely eliminated by alemtuzumab treatment, while it remained at 11% in the ATG group. Addition of alemtuzumab to fludarabine/ cyclophosphamide conditioning has been studied in patients with haematological and other malignancies receiving matched sibling PBSC grafts (n = 36) 70 and mismatched related donor grafts (n = 24). 71 Alemtuzumab (20 mg/day for 5 days) was used with fludarabine (30 mg/m 2 /day, for 5 days, cyclophosphamide 500 mg/m 2 /day for 4 days). There was very little GVHD in the matched sibling group (9% grade 2-4), rather more in the mismatched group (29% grade 2-4), but some patients developed GVHD after donor lymphocyte infusions. All CMV seropositive patients developed antigenaemia but, with early institution of ganciclovir only five developed CMV disease over the two studies. Follow-up was short, and the range of disease treated was heterogenous, but the authors were encouraged by the relatively high numbers of patients who achieved complete remissions, including 13 of 17 treated for NHL. While these studies appear promising, larger cohorts of Bone Marrow Transplantation patients and a longer observation period is obviously required to fully assess the benefits of using alemtuzumab in the setting of NST.
Conclusions
Early results show that alemtuzumab can be used within or prior to conditioning regimens allowing patients with B-CLL to progress to either autologous or to allogeneic transplantation, with the elimination of all detectable residual disease in some cases. A small number of heavily pretreated B-CLL patients have achieved molecular remissions after alemtuzumab therapy and attained durable remission after autologous transplantation. This raises the possibility that, by using alemtuzumab before transplantation at an earlier stage of the disease, the chances of a cure may be substantially increased, while procedure-related toxicity and mortality may be decreased, with a possibility of cure provided to all patients in need with no upper age limit. The total dose typically used to achieve remission in CLL patients with bulky disease (30 mg three times/week for up to 12 weeks, total 1033 mg) is considerably more than that required for immunosuppression in stem cell transplantation (10 or 20 mg per day for 1 to 10 days, total 10 to 100 mg). As yet, few CLL patients have proceeded to allogeneic transplant after disease eradication with alemtuzumab, or have been treated with high-dose alemtuzumab as part of the conditioning. Appropriate choice of dose probably depends on the total mass of lymphocytes to be cleared. To avoid undesirable effects on immune reconstitution it is important that the dose is not too high. Based on the properties of alemtuzumab and the experience in other diseases, it seems likely that this agent will be useful for prevention of rejection and GVHD in all allogeneic transplants, matched, unrelated or even mismatched, and should be especially applicable for non-malignant indications, such as autoimmune diseases, where elimination of self-reactive lymphocytes may be an important component of the procedure. Prospective, randomised, multi-centre clinical trials, will be required to obtain reliable information on the optimal use of alemtuzumab for control of GVHD and rejection, as well as residual disease in patients with lymphoid malignancies.
